Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990)
:6990
6990 Stock Chart & Stats
HK$487.00
-HK$6.30(-3.77%)
At close: 4:00 PM EST
HK$487.00
-HK$6.30(-3.77%)
Day’s Range― - ―
52-Week RangeHK$228.20 - HK$581.00
Previous CloseN/A
Volume210.00K
Average Volume (3M)641.47K
Market Cap
HK$113.56B
Enterprise ValueHK$69.78B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 24, 2026EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding162,769,970
10 Day Avg. Volume649,182
30 Day Avg. Volume641,465
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$539.98Price Target Upside10.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.91
Revenue Forecast (FY)HK$2.72B
Bulls Say, Bears Say
Bulls Say
Commercialization StrategySignificant strides in commercialization with three commercialized assets and plans to expand the commercial team to over 500 employees.
Financial PerformanceKelun-Biotech reported strong financial results, driven by milestone payments from global collaborations and the progression of its innovative pipeline.
Innovation In Drug DevelopmentKelun-Biotech is advancing a multi-pronged ADC strategy across oncology and non-oncology, leveraging novel payloads and next-generation conjugation technologies.
Strategic PartnershipsLicensing and collaboration agreements contributed RMB 1.86bn revenue, reflecting strong partnerships with milestone payments from MSD.
Bears Say
Licensing ConcernsDespite successful out-licensing of SKB378, the significant valuation of up to US$970 million plus royalties may raise concerns about market expectations.
Net LossThe Company narrowed its net loss significantly to RMB 266.8mn, though still operating at a loss despite revenue growth outpacing cost expansion.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H News
6990 FAQ
What was Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price range in the past 12 months?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H lowest stock price was HK$228.20 and its highest was HK$581.00 in the past 12 months.
What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s market cap?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s market cap is HK$113.56B.
When is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date is Aug 24, 2026 which is in 137 days.
How were Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s earnings last quarter?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H released its earnings results on Mar 23, 2026. The company reported -HK$1.026 earnings per share for the quarter, beating the consensus estimate of -HK$1.508 by HK$0.482.
Is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H overvalued?
According to Wall Street analysts Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price is currently Undervalued.
Does Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H pay dividends?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H does not currently pay dividends.
What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s EPS estimate?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s EPS estimate is 0.27.
How many shares outstanding does Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H have?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has 162,769,970 shares outstanding.
What happened to Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H reported an EPS of -HK$1.026 in its last earnings report, beating expectations of -HK$1.508. Following the earnings report the stock price went down -4.789%.
Which hedge fund is a major shareholder of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6990
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$539.98 (10.88% Upside)
HK$539.98 (10.88% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.29%
12-Months-Change
Fundamentals
Return on Equity
-9.29%
Trailing 12-Months
Asset Growth
46.85%
Trailing 12-Months
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Earnings & Revenues
6990 Stock 12 Month Forecast
Average Price Target
HK$539.98
▲(10.88% Upside)
Technical Analysis
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
Akeso, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Giant Biogene Holding Co. Ltd.
―
Options Prices
Currently, No data available
---